Pharmaceutical dosage unit for treating inflammation comprising protease nexin-I
AssigneeIncyte Pharmaceuticals, Inc.
InventorRandal W. Scott
Life of this patent
Estimating the term…
Abstract
Methods and pharmaceutical compositions for treatment of inflammation and arthritis using protease nexin-I as an active ingredient are disclosed.
Claims12
A pharmaceutically acceptable injectable dosage unit for treating inflammation, comprising:
- a pharmaceutically effective amount of protease nexin-I;
- and
- a pharmaceutically acceptable carrier.
A pharmaceutically acceptable, injectable dosage unit for treating inflammation, comprising:
- a pharmaceutically effective amount of protease nexin-I in the range of from about 1 to 10 mg;
- and
- a pharmaceutically acceptable carrier in the form of a physiological saline solution.
A pharmaceutically acceptable, transmucosal dosage unit for treating inflammation, comprising:
- an amount of protease nexin-I sufficient to reduce the loss of glycosaminoglycans from connective tissue and thereby reduce inflammation;
- and
- a pharmaceutically acceptable carrier comprising a bile salt, a fusidic acid derivative, and a detergent.
A pharmaceutically acceptable, transbuccal dosage unit for treating inflammation, comprising:
- an amount of protease nexin-I sufficient to reduce the loss of glycosaminoglycans from connective tissues and thereby reduce inflammation;
- and
- a pharmaceutically acceptable carrier combined with the protease nexin-I in a manner so as to form the transbuccal dosage unit.
A pharmaceutically acceptable, transdermal dosage unit for treating inflammation, comprising:
- an amount of protease nexin-I sufficient to reduce the loss of glycosaminoglycans from connective tissue and thereby reduce inflammation;
- and
- a pharmaceutically acceptable carrier.
A pharmaceutically acceptable, oral dosage unit for treating inflammation, comprising:
- an amount of protease nexin-I sufficient to reduce the loss of glycosaminoglycans from connective tissue and thereby reduce inflammation;
- and
- a pharmaceutically acceptable carrier in the form of an enteric composition which prevents the protease nexin-I from being degraded in the digestive tract.
A pharmaceutically acceptable, aerosol dosage unit for treating inflammation, comprising:
- an amount of protease nexin-I sufficient to reduce the loss of glycosaminoglycans from connective tissue and thereby reduce inflammation;
- and
- pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.